Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Saved in:
| Title: | Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. |
|---|---|
| Authors: | Aamdal E; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Ellingsen EB; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Rasch W; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Brunsvig PF; Department of Oncology, Oslo University Hospital, Oslo, Norway., Aamdal S; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway., Heintz KM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Vodák D; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Nakken S; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Hovig E; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway., Nyakas M; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Guren TK; Department of Oncology, Oslo University Hospital, Oslo, Norway., Gaudernack G; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway. |
| Source: | Frontiers in immunology [Front Immunol] 2021 May 11; Vol. 12, pp. 663865. Date of Electronic Publication: 2021 May 11 (Print Publication: 2021). |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34046035 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Aamdal+E%22">Aamdal E</searchLink>; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.<br /><searchLink fieldCode="AU" term="%22Inderberg+EM%22">Inderberg EM</searchLink>; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Ellingsen+EB%22">Ellingsen EB</searchLink>; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Rasch+W%22">Rasch W</searchLink>; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Brunsvig+PF%22">Brunsvig PF</searchLink>; Department of Oncology, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Aamdal+S%22">Aamdal S</searchLink>; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Heintz+KM%22">Heintz KM</searchLink>; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Vodák+D%22">Vodák D</searchLink>; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Nakken+S%22">Nakken S</searchLink>; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Hovig+E%22">Hovig E</searchLink>; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Nyakas+M%22">Nyakas M</searchLink>; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Guren+TK%22">Guren TK</searchLink>; Department of Oncology, Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Gaudernack+G%22">Gaudernack G</searchLink>; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2021 May 11; Vol. 12, pp. 663865. <i>Date of Electronic Publication: </i>2021 May 11 (<i>Print Publication: </i>2021). – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34046035 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fimmu.2021.663865 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 663865 Titles: – TitleFull: Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Aamdal E – PersonEntity: Name: NameFull: Inderberg EM – PersonEntity: Name: NameFull: Ellingsen EB – PersonEntity: Name: NameFull: Rasch W – PersonEntity: Name: NameFull: Brunsvig PF – PersonEntity: Name: NameFull: Aamdal S – PersonEntity: Name: NameFull: Heintz KM – PersonEntity: Name: NameFull: Vodák D – PersonEntity: Name: NameFull: Nakken S – PersonEntity: Name: NameFull: Hovig E – PersonEntity: Name: NameFull: Nyakas M – PersonEntity: Name: NameFull: Guren TK – PersonEntity: Name: NameFull: Gaudernack G IsPartOfRelationships: – BibEntity: Dates: – D: 11 M: 05 Text: 2021 May 11 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1664-3224 Numbering: – Type: volume Value: 12 Titles: – TitleFull: Frontiers in immunology Type: main |
| ResultId | 1 |
